CSL Behring (CSL Limited)

What does CSL Behring own?
CSL Behring owns a portfolio of plasma-derived therapy brands including Privigen, Hizentra, Kcentra, Haegarda, Streptase, and albumin products. As part of CSL Limited, it is associated with CSL Seqirus (influenza vaccines including Afluria and Flucelvax) and CSL Vifor (Ferinject and Venofer for iron deficiency). CSL Plasma operates the world's largest plasma collection network with over 300 centers.

Is CSL Behring publicly traded?
CSL Behring is a division of CSL Limited, which trades on the Australian Securities Exchange under ticker CSL. CSL Limited is a component of the S&P/ASX 20 Index. The company completed its IPO in June 1994 at A$2.30 per share. CSL Behring itself is not separately listed but contributes the majority of CSL Limited's revenue.

Who founded CSL?
CSL was founded in 1916 by the Australian government as Commonwealth Serum Laboratories, a federal body focused on vaccine manufacture. William Penfold, recruited from the Lister Institute in London, served as the first director. The organization was privatized in 1994 by the Keating government and listed on the Australian Securities Exchange.

What is CSL Behring's main business?
CSL Behring develops, manufactures, and markets plasma-derived therapies for rare and serious diseases. Its primary products are immunoglobulins for immune deficiencies, albumin for shock and burns, and clotting factors for hemophilia. The division is the core earnings driver for CSL Limited, generating the majority of the group's revenue from chronic disease patients requiring lifelong treatment.

What were CSL's FY2025 financial results?
CSL Limited reported FY2025 (fiscal year ended June 2025) revenue of US$15.6 billion, up 5.1% from FY2024. Net income was US$3.0 billion, and underlying profit (NPATA) increased 14% to US$3.3 billion on a constant currency basis. The company declared dividends of US$1.62 per share, a 12% increase from FY2024.

What happened with the Vifor acquisition?
CSL acquired Vifor Pharma for $11.7 billion in 2022, adding iron deficiency and nephology treatments to its portfolio. The acquisition has underperformed expectations, with generic competition in iron products and the revocation of marketing authorization for Tavenos. FY2026 impairment charges related to Vifor and other assets totaled US$5.4 billion, contributing to a net loss of US$2.58 billion.

What is the Seqirus demerger plan?
In August 2026, CSL announced plans to demerge its CSL Seqirus influenza vaccine business into a separately listed entity. Management framed the separation as giving Seqirus autonomy to pursue opportunities in the vaccines market. However, the plan was subsequently put on hold after the company determined that proceeding would not maximize shareholder value.

CSL Limited's origins date to 1916, when the Australian government established Commonwealth Serum Laboratories in Parkville, Melbourne, to ensure the nation had domestic access to vaccines and biological products during World War I. William Penfold, recruited from the Lister Institute in London, served as the first director. CSL commenced operations in 1918 in the vacant Walter and Eliza Hall Institute building before moving to purpose-built Parkville premises in 1919.

Over the following decades, CSL achieved numerous milestones in public health. The organization produced insulin for Australian diabetics in 1923, developed a tetanus vaccine in 1938, and began plasma fractionation in 1952. CSL pioneered heat treatment of blood and plasma products to protect against HIV infection in 1983. The organization also collaborated on the development of Gardasil, the world's first human papillomavirus vaccine, between 1994 and 2005.

In 1994, the Keating government privatized CSL through an initial public offering on the Australian Securities Exchange at A$2.30 per share. The newly listed company faced the challenge of building a global business from a domestic government laboratory.

The transformation into a global plasma leader began in 2000, when CSL acquired ZLB Bioplasma AG, a Bern-based Swiss plasma company, doubling the company's size. In 2004, during a period of plasma oversupply, CSL expanded again with the purchase of German medical company Aventis Behring. These acquisitions formed the foundation of what became CSL Behring, combining ZLB's plasma fractionation capabilities with Aventis Behring's product portfolio and manufacturing infrastructure.

In October 2014, Novartis agreed to sell its influenza vaccine business to CSL for $275 million. CSL merged this business with its existing BioCSL operation, rebranding the combined entity as Seqirus in November 2015. This created the world's second-largest influenza vaccine company.

In December 2021, CSL announced the acquisition of Swiss drugmaker Vifor Pharma for $11.7 billion, completed in 2022. This added iron deficiency and nephrology treatments to the portfolio. In August 2022, CSL rebranded all divisions with the CSL prefix, creating CSL Behring, CSL Plasma, CSL Seqirus, and CSL Vifor.

In FY2026 (fiscal year ended June 2026), CSL reported revenue of US$15.8 billion but recorded a net loss of US$2.58 billion due to US$5.4 billion in restructuring and impairment charges. The company announced plans to demerge CSL Seqirus into a separately listed entity, though this plan was later put on hold. CEO Paul McKenzie retired in February 2026 after seven years with the company, and Gordon Naylor was appointed interim CEO.

CSL publishes annual sustainability reports and has established environmental, social, and governance commitments. The company's sustainability strategy focuses on access to medicines, environmental responsibility, and ethical business practices.

CSL's plasma collection operations are subject to extensive regulatory oversight, including FDA inspections in the United States and equivalent regulatory bodies in other markets. The company maintains compliance programs covering donor safety, product quality, and supply chain integrity.

The company has faced scrutiny regarding plasma donor compensation practices. CSL Plasma operates collection centers that compensate donors for their time, a standard practice in the industry but one that has drawn ethical debate about whether it exploits economically vulnerable populations. The majority of the world's plasma supply comes from paid donors in the United States.

CSL's acquisition strategy has drawn investor scrutiny. The $11.7 billion Vifor acquisition in 2022 has underperformed expectations, with generic competition and regulatory setbacks reducing the division's revenue. The FY2026 impairment charges of US$5.4 billion included write-downs related to this acquisition, raising questions about due diligence and valuation.

The company's Seqirus vaccine business faced challenges during and after the COVID-19 pandemic, including supply chain disruptions and changing public attitudes toward vaccination. CSL was involved in COVID-19 vaccine development, with its Seqirus division contributing to manufacturing capabilities.

CSL has faced regulatory and public scrutiny typical of large pharmaceutical companies operating in highly regulated markets globally.

In 1928, CSL was involved in the Bundaberg tragedy, in which twelve children died after receiving a batch of diphtheria toxin-antitoxin. Although CSL's manufacturing processes were absolved, its labelling procedures were found to be in error, leading to a sustained focus on production standards at the facility.

The company's plasma collection and fractionation operations are subject to rigorous regulatory oversight by the FDA, EMA, and other regulatory bodies. Plasma-derived therapies carry inherent risks of pathogen transmission, requiring robust screening and viral inactivation processes.

The Vifor acquisition has been a source of investor frustration. The $11.7 billion purchase price has not been justified by subsequent performance, with the division facing generic competition and regulatory setbacks. The FY2026 impairment charges related to Vifor and other assets totaled US$5.4 billion, contributing to the company's first reported net loss in recent history.

The announced Seqirus demerger plan was put on hold after management determined that proceeding would not maximize shareholder value. The reversal, combined with the CEO departure and restructuring charges, created a period of leadership and strategic uncertainty for the company.